---
title: "EGFR TKI-as-Targeted therapy-of-NSCLC"
slug: "egfr-tki-as-targeted-therapy-of-nsclc"
date: "2023-11-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Targeted therapy-of-NSCLC]]

# EGFR TKI-as-Targeted therapy-of-NSCLC

- EGFR classical sensitizing mt (exon 19 deletion or L858R):
- Initial tx:
  - osimertinib (ORR 80%, PFS 18.9 mos) 
      - (NEJM 2018;378:113)
      - [[Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer]]
  - erlotinib & Bev (ORR 59%, PFS 10.1 mos).
  - Prior care standards:
    - Erlotinib, gefitinib, afatinib, dacomitinib â†‘ PFS, improved RR/PFS compared to plat doublet in 1st line (IPASS, NEJM 2010;362:2380).
  - S/e:
    - Rash (30-50% pts, Tx: Moisturizers, abx, topical steroids),
    - diarrhea
- Subsequent tx for EGFR T790M+ (50% resistance cases):
- [[Osimertinib]]
  - (if treated w/ erlotinib, gefitinib, afatinib, or dacomitinib) (NEJM 2015;372:1689) or progressive CNS dz, chemo if T790M-or continuation of TKI Â± local Rx for progression (JCO 2013;31:3335)
- Adj. tx after tumor resection:
  - Osimertinib
- EGFR uncommon/atypical mt (S768O, L861Q, G719X):
  - Afatinib, osimertinib
- EGFR exon 20 insertion mt
  - 2L+ amivantamab, EGFR-MET bispecific (ORR 40%, PFS 8.3 mo) (JCO 2021;39(30):3391) or 2L+ mobocertinib, EGFR TKI (ORR 28%, PFS 7.3 mos) (Cancer Discov 2021;11(7):1688)
